472 related articles for article (PubMed ID: 26078392)
1. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.
Crowther GS; Chilton CH; Longshaw C; Todhunter SL; Ewin D; Vernon J; Karas A; Wilcox MH
J Antimicrob Chemother; 2016 Apr; 71(4):986-91. PubMed ID: 26755495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
[TBL] [Abstract][Full Text] [Related]
6. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
[TBL] [Abstract][Full Text] [Related]
8. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
9. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
12. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
[TBL] [Abstract][Full Text] [Related]
13. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH
J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
20. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Baines SD; Wilcox MH
J Antimicrob Chemother; 2014 Aug; 69(8):2137-47. PubMed ID: 24788662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
